Dr. Eric Huseman

Dr. Eric HusemanMarquette University

Wehr Chemistry Building, 654

MilwaukeeWI53201United States of America(414) 288-7374eric.huseman@marquette.eduThe Huseman Lab

Assistant Professor

Organic Synthesis and Carbohydrate Chemistry

Education

Ph.D., Vanderbilt University

B.Sc., Cedarville University

Research Interests

The Huseman Group is a synthetic organic chemistry group specializing in the development of new methods for carbohydrate synthesis and modification. Carbohydrates play pivotal roles in biological processes such as metabolism, protein folding, and cell-to-cell communication. They feature prominently in pharmaceuticals used in the treatment of diseases ranging from diabetes to cancer. Structurally, carbohydrates are stereochemically complex and rich in heteroatoms (namely oxygen). These factors complicate their chemical manipulation and, ultimately, the study of their biological properties. As synthetic chemists, we view these structural challenges as opportunities to develop new chemistry that will facilitate biological studies and medicinal chemistry campaigns.

Professional Experience

Eric Huseman conducted his graduate studies under the direction of Prof. Steven D. Townsend at Vanderbilt University. At Vanderbilt, he completed the total synthesis of the natural product Arimetamycin A and related derivatives. After obtaining his Ph.D. in 2021, he continued his training as a postdoctoral associate under the direction of Prof. Seth B. Herzon at Yale University. At Yale, he studied the mechanism of action of KL-50, a novel DNA crosslinker that selectively targets drug-resistant brain cancers. Following the completion of his postdoctoral training, he joined the chemistry faculty at Marquette University in August of 2023 as an Assistant Professor.

Selected Publications

Please see the full list on Google Scholar.

1. Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers. Huseman, E. D.; Lo, A.; Fedorova, O.; Elia, J. L.; Gueble, S. E.; Lin, K.; Sundaram, R. K.; Burgenske, D. M.; Oh, J.; Liu, J.; Menges, F. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Batista, V. S.; Crawford, J. M.; Sarkaria, J. N.; Pyle, A. M.; Bindra, R. S.; Herzon, S. B. Chemrxiv. Cambridge: Cambridge Open Engage; 2023. doi.org/10.26434/chemrxiv-2023-zwj94 
2. Mechanism-based Design of Agents that Selectively Target Drug-Resistant Glioma. Lin, K.; Gueble, S. E.; Sundaram, R. K.; Huseman, E. D.; Bindra, R. S.; Herzon, S.B. Science 2022, 377, 502-511 doi.org/10.26434/chemrxiv-2023-zwj94
3. Synthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids. Huseman, E. D.; Byl, J. W.; Chapp, S. M.; Schley, N. D.; Osheroff, N.; Townsend, S. D.  ACS Cent. Sci. 2021, 7, 1327-1337. doi.org/10.1021/acscentsci.1c00040
4. De novo Synthesis of an L-Lemonose Thioglycoside Donor from D-Threonine. Huseman, E. D.; Townsend, S. D. Tetrahedron Lett. 2021, 73, 153097. doi.org/10.1016/j.tetlet.2021.153097